Aker BioMarine ASA (Public, OSL:AKBM) is a Norwegian fishing and seafood processing company. Based in Oslo, it operates three krill fishing vessels in Antartica, Argentina and the Faroe Islands.
Aker BioMarine is an integrated biotechnology company that develops, markets and sells krill- based ingredients for both the consumer and animal-feed markets.
Aker BioMarine is a wholly-owned subsidiary. The shareholding is valued at NOK 1.4 billion (book value). This equates to 3 per cent of Aker’s total assets at 31 December 2017. Kjell Inge Røkke, Øyvind Eriksen and Frank O. Reite represent Aker on the com- pany’s board of directors.
AKER’S OWNERSHIP AGENDA
Aker BioMarine is vertically integrated and controls the entire supply chain, from sustainable krill harvesting in the Antarctic to innovative product development, production, logistics and marketing. Pro table growth is at the forefront of Aker’s own- ership agenda. This entails focus on establishing sound oper- ations and e ective value chains in the industries where Aker BioMarine is a supplier.
IN OPERATION FROM 2019: The new 130-metre-long krill vessel will be equipped with the latest and most advanced eco-friendly technology. This will give additional power to Aker Biomarines already strong sustainability commitments. Illustration: Aker Biomarine / Vard
The company has built a long-term partnership with branded consumer goods companies, environmental protection organ- isations and researchers. SuperbaTM Krill Oil, the company’s brand ingredient in the Omega-3 consumer market, has estab- lished a strong position in the global market. Demand for QrillTM Aqua, a feed supplement for the aquaculture industry, is still good, and the product range has been expanded with feed in- gredients for farm animals.
In 2017, Aker BioMarine acquired the krill business of Neptune Technologies & Bioresources Inc. and in January 2018 the com- pany acquired the krill business from Enzymotec. In 2017, Aker BioMarine bought the krill vessel “Juvel”, and the company now has three vessels and three krill harvesting licences. A new and modern vessel was ordered in 2017 to be ready to begin shing in early 2019. Aker BioMarine’s growth and investments requires funding from Aker. Aker is working to maximise Aker BioMarine’s underlying value, and continuing to assess strate- gic opportunities for further growth, including making Aker’s investment more liquid.
The Company has four wholly owned subsidiaries, including, Aker BioMarine Antarctic AS, Krill AS, Natural Nutrition Development AS and Natural USA Inc. Aker BioMarine ASA has also a 50% stake in O3C Nutraceuticals AS.